ClinicalTrials.gg
RecruitingNCT07791355Updated Aug 27, 2026

Pain Reprocessing Therapy (PRT) in a Specialist Pain Clinic: A Feasibility Study

An interventional study of Pain Reprocessing Therapy in Chronic Pain, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Chronic Pain with a site in Sweden — 30 open to participants now, 37 under way, none of them phase 3. Chronic Pain · Sweden.

Planned enrollment
54th of 65
25 · median 80
Started
2026
with 8 others
No phase
61 of 88
23 open now
Primary completion
2027-07
later than 20 of 36 live
Registered
86th of 88
by date
Lead sponsor
7 of 88
Karolinska Institutet

Among the 88 studies in Chronic Pain with a site in Sweden, this one is the 54th largest by planned enrollment of the 65 interventional ones that give a count, is one of 9 that started in 2026, is one of 61 with no phase, reaches primary completion later than 20 of the 36 other live ones, and was the 86th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

30 of the 88 studies in Chronic Pain with a site in Sweden are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Chronic Pain with a site in Sweden, or all of them as a file.
02

Study summary

Long-term pain, which is pain that lasts for more than three months, is a major health problem. It can severely impact a person's physical and mental well-being, quality of life, and ability to work. It also carries high costs for society, mainly due to high rates of sick leave.

For many people with long-term pain, there is no clear injury or disease that fully explains why it hurts. In these cases, the pain is believed to be caused by how the brain and nervous system process pain signals. This is sometimes called "nociplastic pain."

Even though there are many treatments for pain-like medications and therapies-they don't work for everyone, and many people are left without meaningful relief. Because of this, it is important to find and test new ways to treat pain. In this study, the investigators evaluate a relatively new psychological treatment called Pain Reprocessing Therapy (PRT), which has been tested in the US with promising results.

PRT helps individuals with chronic pain to understand and change how they think about their pain by explaining how the brain works. The treatment focuses on teaching the difference between acute (new) pain and long-term pain. It also involves exercises to help people alter emotions related to their pain. A key part of the treatment is a technique where patients practice paying attention to what is happening in their bodies in a safe, relaxed way. The goal is to teach the brain that the pain signals are not a threat. This can help break the vicious cycle of fear, avoiding activities, and worsening pain.

While many people are interested in treatments like PRT, it hasn't yet been tested in specialized care for patients with complex pain. This trial is a pilot study-a smaller, initial investigation to evaluate how well the treatment works in a clinical setting, and to determine if both patients and therapists find it acceptable and practical to use. This will give us important information to help prepare for larger studies in the future.

The main goal of this pilot study is to see if PRT is a practical and accepted treatment in a Swedish pain rehabilitation setting. The investigators also want to look at whether the treatment helps reduce pain, psychological distress, negative thoughts about pain, and the fear of moving. Finally, the investigators will explore how a patient's expectations and thinking skills (such as memory and focus) might affect how well the treatment works, and take physical measurements before and after the treatment to see if the nervous system becomes better at regulating pain.

Read the detailed description

The overall aim of this project is to conduct a pilot study investigating the feasibility, patient satisfaction, and acceptability of a recently developed psychological treatment for pain: Pain Reprocessing Therapy (PRT). The study will be conducted within a clinical pain rehabilitation setting, where patients frequently present with severe pain, psychiatric comorbidity, and reduced or absent work capacity.

Within the framework of this project, the investigators will evaluate whether PRT can be effectively implemented in a pain rehabilitation context and whether the treatment is perceived as acceptable and feasible by both patients and clinicians. Furthermore, the investigators intend to conduct exploratory analyses to determine if specific clinical subgroups appear more responsive to the intervention.

A secondary aim is to evaluate changes in pain intensity, functional capacity, fear of movement (kinesiophobia), pain catastrophizing, as well as symptoms of anxiety and depression. Although study participants will not be randomized, the results will be compared to a matched reference group drawn from the Swedish Quality Registry for Pain Rehabilitation (SQRP). This reference group, comprising individuals who have undergone standard multimodal pain rehabilitation, is included to provide a contextualizing indication of whether PRT is associated with clinically relevant changes in the outcome measures.

The project is designed as a single-arm pilot study in which all participants will receive PRT. Data collection will occur at baseline, during the intervention, and post-treatment. PRT, which has previously been evaluated primarily in a selected population with chronic back pain and limited comorbidity, aims to modify the patient's interpretation of the cause of their pain and its perceived threat value. By targeting fear-avoidance responses triggered by somatic signals, the ultimate objective of the treatment is to facilitate sustained symptom relief.

Primary Objective:

The primary objective is to investigate whether a 9-week treatment with Pain Reprocessing Therapy (PRT) meets predefined criteria for feasibility and acceptability.

Primary Research Questions:

  • Is an adequate recruitment rate achieved among approached patients?
  • Does a sufficiently large proportion of the included participants complete the treatment program (retention rate)?
  • Does the treatment demonstrate adequate patient satisfaction?
  • Are patient attendance and treatment adherence, in terms of completing homework assignments, consistent with predefined benchmarks?
  • Do the clinicians demonstrate adequate treatment fidelity to the PRT manual?

Secondary Objective:

The secondary objective is to exploratively investigate whether PRT is associated with changes in predefined clinical outcome measures.

Secondary Research Questions:

  • Are there observed changes in self-rated pain experience, quality of life, symptoms of anxiety and depression, fear of movement (kinesiophobia), pain-related catastrophizing, fatigue and sickness behavior?
  • How do changes in outcome measures following PRT compare to a matched reference group that has undergone standard multimodal pain rehabilitation?

Exploratory Research Questions:

  • Are participants' initial treatment expectations and perceived credibility , as well as their perception of clinician empathy, cognitive functioning and pain sensitivity associated with treatment outcomes?
  • How are cognitive function and pain sensitivity affected by the treatment?
  • How do participants describe their experiences of the treatment and perceived processes of change in qualitative interviews?
03

Conditions studied

  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and older.
  • Completed medical investigation regarding the pain diagnosis. Primary pain conditions (according to ICD-11) or nociplastic pain, as well as mixed conditions where patients have nociplastic pain combined with nociceptive and/or neuropathic pain (e.g., fibromyalgia, chronic widespread pain, primary chronic back pain).
  • Pain duration of at least 3 months.
  • Current medication regimen compatible with participating in and benefiting from highly specialized rehabilitation.
  • Ability to read, speak, and understand the Swedish language.

Exclusion criteria

  • Severe psychiatric conditions (e.g., psychosis, severe depression, and suicidality).
  • Current substance abuse (including overuse of prescription medications) or dementia.
  • Cancer pain, cauda equina syndrome, or other medical conditions that constitute the primary explanation for the patient's pain.
  • Another psychological treatment for pain within the past 3 months.
  • Ongoing parallel treatments related to the patient's pain at other clinics, with the exception of ongoing pharmacological treatment.
  • Ongoing legal disputes or active claims for disability compensation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Pain Reprocessing Therapy

    Behavioral: Pain Reprocessing Therapy

Interventions

  • BehavioralPain Reprocessing Therapy

    A 9-week intervention with 9 individual sessions and 3 group sessions based on Pain Reprocessing Therapy.

06

What researchers measure

Primary outcomes

  1. Retention rate

    The retention rate is defined as the percentage of participants who successfully complete the PRT intervention. To be considered a completer, a participant must attend at least 6 of the 9 individual sessions and complete all post-treatment outcome measures. The benchmark for study feasibility is set at 75%

    Time frame: From enrollment to 9 weeks (post treatment).

  2. Recruitment rate

    Feasibility of recruitment, defined as percentage of eligible participants who give informed consent and are enrolled in the study. The predefined benchmark for feasibility of recruitment rate is set as at least 70%

    Time frame: From study start to recruitment completion, an estimated 6 months

  3. Patient treatment satisfaction

    Assessed using the Client Satisfaction Questionnaire (CSQ-8). The total score ranges from 8 to 32. Higher scores indicate greater satisfaction with the treatment received, representing a better outcome. The predefined benchmark for acceptability is set to a mean total score of 24 or higher (out of a maximum of 32).

    Time frame: Post treatment (9 weeks)

  4. Adherence to treatment

    Adherence to the in-between session work with home assignments, as logged by the therapists during the 9-week program. The predefined benchmark for adequate adherence is at least 70% of assigned homework tasks.

    Time frame: From enrollment to the end of the treatment at 9 weeks

  5. Therapists treatment fidelity

    The degree to which the therapists adhere to the core interventions of the treatment. Evaluated by therapist self-report using a study-specific PRT fidelity checklist completed after each session. The predefined benchmark for adequate treatment fidelity is set to an average adherence score of at least 80%.

    Time frame: From treatment start to the end of treatment at 9 weeks

Secondary outcomes

  1. Pain Catastrophizing Scale (PCS)

    The PCS assesses negative thoughts and emotions associated with past, present or anticipated pain. The total score ranges from 0 to 52. Higher scores indicate greater levels of pain catastrophizing.

    Time frame: Baseline and week 9

  2. Tampa Scale of Kinesiophobia (TSK)

    The TSK assesses fear of movement or re-injury. The 17-item version is used. Total scores range from 17 to 68. Higher scores indicates a higher degree of kinesiophobia.

    Time frame: Baseline and week 9

  3. Hospital Anxiety and Depression Scale (HADS)

    The HADS scale measures anxiety and depression symptoms. The HADS contains of 14 items, divided into 2 subscales (anxiety and depression). For each subscale, the total score ranges from 0 to 21. Higher scores indicate greater severity of anxiety and depression symptoms.

    Time frame: Baseline and week 9

  4. EQ-5D

    The EQ-5D measures health-related quality of life across five dimensions. Responses are converted into a single index score. The index score typically ranges from a minimum of less than 0 (often around -0.59, representing a health state worse than death) to a maximum of 1.0 (representing full health). Higher index scores indicate a better health-related quality of life.

    Time frame: Baseline and week 9 (post treatment)

  5. EQ-5D VAS

    Measures self-rated overall health using a Visual Analogue Scale (EQ-VAS). Participants rate their overall health using a vertical visual analogue scale rangeing from 0-100. Higher scores indicates a better self-percieved health.

    Time frame: Baseline to 9 week (post treatment)

  6. Sickness Questionnaire (SicknessQ)

    The SicknessQ assesses self-reported sickness behavior (e.g., fatigue, social withdrawal. The scores ranges from 0 tp 30. Higher scores indicate a higher degree of sickness behavior.

    Time frame: Baseline and week 9.

  7. Multidimensional Fatigue Inventory (MFI-20)

    The MFI-20 assesses five dimensions of fatigue. The total score ranges from 20-100 where higher scores indicate higher levels of fatigue.

    Time frame: Baseline to 9-week (post treatment)

  8. Numeric Rating Scale For Pain

    The NRS measures pain intensity where participants rate their pain intensity during the past week on an 11 point scale from 0 to 10. Higher scores indicate worse pain intensity.

    Time frame: Baseline and week 9 (Post treatment)

  9. Consultation and Relational Empathy Measure (CARE)

    The CARE-scale assesses the participants perception of the therapists empathy during sessions. The maximum score is 50. Higher scores indicate greater percieved empathy from the treating clinician

    Time frame: Week 2 and 9 (post treatment)

  10. Credibility/Expectancy Questionnaire (CEQ)

    The CEQ assesses how logical the treatment seems to the patient, and how much improvement they expect. Scores for each subscale range from 3 to 27. Higher scores indicate higher perceived credibility and expectancy of clinical improvement.

    Time frame: Week 2

Other outcomes

  1. Pressure Pain Threshold (PPT)

    Assessed using a pressure algometer. Measures are recorded in kPa at predefined anatomical sites. Higher values indicate higher pain thresholds.

    Time frame: Baseline and 9-week

  2. Thermal Pain Thresholds

    Assessed using a computerized thermotest device. Heat Pain Threshold (HPT) and Cold Pain Threshold (CPT) are measured in degrees Celcius. For HPT, higher temperatures indicate a higher pain threshold. For CPT, lower temperatures indicate a higher pain threshold.

    Time frame: Baseline and week 9 (Post treatment)

  3. PrePain Questionnaire

    The PrePain questionnaire assesses attitudes, emotions and behaviors related to pain. The six dimensional questions (assessing perceived pain-sensitivity, avoidance, distress, relief, focus on symptoms, and negative thoughts) are analyzed individually rather than as a total score. Each item is scored on a Visual Analog Scale (VAS) with a minimum value of 0 and a maximum value of 100. A VAS-score of 100 means respectively low pain-sensitivity, low degree of avoidance, low degree of distress, low degree of relief, low degree focus on symptoms and low degree of negative thoughts. Because higher scores represent a lower degree of these pain-related attitudes and emotions, higher scores indicate a better outcome.

    Time frame: Before treatment start and 9 weeks (post treatment)

  4. Stroop-test

    Executive control, attention, and inhibition are assessed using a digital version of the Stroop test administered via the 'Health Catcher' application. Participants are instructed to respond to the color of a written word rather than the word itself. Performance is measured by the total number of correct responses completed within a 90-second time limit. The minimum possible score is 0. There is no predefined maximum score, as the total number of items presented depends on the participant's response speed. Higher scores (more correct responses within the time limit) indicate better cognitive performance and inhibition.

    Time frame: Baseline and 9 weeks (post treatment)

  5. Go/no-go Test

    Sustained attention and response inhibition are assessed using a digital Go/no-go test administered via the 'Health Catcher' application. Participants respond to a target stimulus while withholding responses to a non-target stimulus. Performance is measured by the total number of correct responses completed within a 90-second time limit. The minimum possible score is 0. There is no predefined maximum score, as the total number of items presented depends on the participant's response speed. Higher scores (more correct responses within the time limit) indicate better sustained attention and response inhibition.

    Time frame: Baseline and 9 weeks (post treatment)

  6. Verbal Recognition Memory Test

    Verbal episodic memory is assessed using a digital verbal recognition memory test administered via the 'Health Catcher' application. Participants report whether mixed lists of words were included in a previously presented sequence. Performance is measured by the total score of correct recognitions. The score ranges from a minimum of 0 to a maximum of 24. Higher scores indicate better memory function.

    Time frame: Baseline and 9 weeks (post treatment)

  7. Visual Working Memory Test

    Visuospatial working memory and attention are assessed using a digital visual working memory test administered via the 'Health Catcher' application. Participants memorize and reproduce sequences of illuminated squares in a 4x4 grid. Performance is measured by the total score of correctly identified locations. The score ranges from a minimum of 0 to a maximum of 6. Higher scores indicate better visuospatial working memory, representing a better outcome

    Time frame: Baseline and 9 weeks (post treatment)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jul 2027, 11 months later.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 11 months is below that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 27, 2026
StartEst.
Aug 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07791355
Collaborators
Region Stockholm
Responsible party
Maria Lalouni (Associate Professor, Karolinska Institutet) — Principal investigator
First posted
Aug 27, 2026
Start date
Aug 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion